Your browser is no longer supported. Please, upgrade your browser.
Settings
SUPN Supernus Pharmaceuticals, Inc. daily Stock Chart
SUPN [NASD]
Supernus Pharmaceuticals, Inc.
Index- P/E16.87 EPS (ttm)1.90 Insider Own1.30% Shs Outstand52.88M Perf Week-0.03%
Market Cap1.70B Forward P/E12.18 EPS next Y2.63 Insider Trans-2.83% Shs Float50.54M Perf Month3.25%
Income103.00M PEG0.46 EPS next Q0.58 Inst Own98.94% Short Float13.71% Perf Quarter-11.77%
Sales403.90M P/S4.20 EPS this Y63.20% Inst Trans0.51% Short Ratio13.70 Perf Half Y-15.66%
Book/sh9.17 P/B3.50 EPS next Y16.55% ROA10.90% Target Price57.25 Perf Year-40.85%
Cash/sh5.54 P/C5.79 EPS next 5Y37.00% ROE23.60% 52W Range29.60 - 56.40 Perf YTD-3.40%
Dividend- P/FCF12.66 EPS past 5Y22.00% ROI14.70% 52W High-43.10% Beta1.54
Dividend %- Quick Ratio2.60 Sales past 5Y102.50% Gross Margin96.10% 52W Low8.41% ATR0.91
Employees448 Current Ratio2.80 Sales Q/Q-5.40% Oper. Margin34.30% RSI (14)48.57 Volatility2.45% 2.86%
OptionableYes Debt/Eq0.69 EPS Q/Q-30.70% Profit Margin25.50% Rel Volume0.53 Prev Close32.02
ShortableYes LT Debt/Eq0.69 EarningsAug 06 AMC Payout0.00% Avg Volume505.76K Price32.09
Recom1.70 SMA200.18% SMA50-0.14% SMA200-14.88% Volume266,109 Change0.22%
Nov-12-18Reiterated B. Riley FBR Buy $68 → $65
Jan-18-18Reiterated B. Riley FBR, Inc. Buy $54
Dec-28-17Reiterated B. Riley FBR, Inc. Buy $50 → $54
Dec-04-17Upgrade Janney Neutral → Buy
Nov-08-17Upgrade Stifel Hold → Buy $47
Oct-19-17Initiated FBR & Co. Buy $53
Sep-19-17Downgrade Stifel Buy → Hold $47
Jul-17-17Downgrade Piper Jaffray Overweight → Neutral
Jul-14-17Initiated Janney Neutral
Jun-01-17Upgrade Piper Jaffray Neutral → Overweight
Jul-18-16Downgrade Piper Jaffray Overweight → Neutral
Jul-18-16Downgrade Northland Capital Outperform → Market Perform
Feb-08-16Upgrade Jefferies Hold → Buy
Nov-05-15Reiterated Northland Capital Outperform $26 → $27
Oct-28-15Initiated Northland Capital Outperform $26
Jun-18-15Upgrade Jefferies Hold → Buy $11 → $18
Jun-18-15Reiterated Stifel Buy $15 → $22
Jun-12-15Initiated Sun Trust Rbsn Humphrey Buy $30
Jun-09-15Initiated Guggenheim Buy $21
Mar-14-14Reiterated Stifel Buy $12 → $14
Jul-11-19 12:58PM  4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal Zacks
Jun-17-19 12:39PM  How Do Analysts See Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Performing Over The Next Year? Simply Wall St.
Jun-11-19 11:04AM  Heres What Hedge Funds Think About Supernus Pharmaceuticals Inc (SUPN) Insider Monkey
Jun-05-19 07:04AM  Edited Transcript of SUPN earnings conference call or presentation 8-May-19 1:00pm GMT Thomson Reuters StreetEvents
May-30-19 03:03PM  Read This Before You Buy Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Because Of Its P/E Ratio Simply Wall St.
May-29-19 04:15PM  Supernus to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-16-19 08:10AM  5 Sizzling Small-Cap Stocks to Buy Today InvestorPlace
May-08-19 03:00PM  3 Top Value Stocks to Buy in May Motley Fool
May-07-19 10:14PM  EA, Supernus Pharmaceuticals, and More: Stocks on the Move After Hours Insider Monkey
07:35PM  Supernus Pharmaceuticals (SUPN) Lags Q1 Earnings and Revenue Estimates Zacks
06:31PM  Supernus: 1Q Earnings Snapshot Associated Press
05:09PM  Supernus Announces First Quarter 2019 Financial Results GlobeNewswire
May-05-19 10:22AM  Are Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Interest Costs Too High? Simply Wall St.
May-01-19 11:55AM  Heres What Hedge Funds Think About Supernus Pharmaceuticals Inc (SUPN) Insider Monkey
Apr-30-19 10:32AM  Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-29-19 09:17AM  2 Incredibly Cheap Value Stocks to Buy Now Motley Fool
Apr-24-19 04:15PM  Supernus to Host First Quarter 2019 Earnings Conference Call GlobeNewswire
Apr-18-19 08:08AM  A Note On Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) ROE and Debt To Equity Simply Wall St.
Apr-01-19 04:46PM  Supernus' ADHD Candidate Positive in 4th Phase III Study Zacks
04:15PM  Supernus Announces Webcast of Investor Day on April 16, 2019 GlobeNewswire
10:57AM  Shareholders Are Thrilled That The Supernus Pharmaceuticals (NASDAQ:SUPN) Share Price Increased 296% Simply Wall St.
Mar-28-19 08:29PM  Edited Transcript of SUPN earnings conference call or presentation 8-Aug-18 1:00pm GMT Thomson Reuters StreetEvents
08:29PM  Edited Transcript of SUPN earnings conference call or presentation 27-Feb-19 2:00pm GMT Thomson Reuters StreetEvents
03:10PM  Supernus reports mixed ADHD drug trial results. So why isn't it worried? American City Business Journals
08:00AM  Supernus Announces P304 Phase III Data Confirming Positive Results from Previous Three Phase III Studies on SPN-812 in ADHD GlobeNewswire
Mar-27-19 06:03PM  Supernus Hosts Conference Call to Present Topline Results of Final Phase III Study for SPN-812 in Adolescents with ADHD GlobeNewswire
Mar-14-19 10:41AM  What Investors Should Know About Supernus Pharmaceuticals, Inc.s (NASDAQ:SUPN) Financial Strength Simply Wall St.
Mar-07-19 07:20AM  Recent Analysis Shows Golar LNG, AG Mortgage Investment Trust, AmerisourceBergen, Caesarstone, Dycom Industries, and Supernus Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-06-19 04:10PM  Supernus to Present at the 2019 Cowen Health Care Conference GlobeNewswire
Mar-01-19 02:48PM  Supernus Pharmaceuticals Inc (SUPN) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
02:22PM  New Enterprise Associates is raising its biggest fund yet. Here's how much it's going for. American City Business Journals
05:00AM  Supernus Pharmaceuticals- Migraines, Epilepsy and ADHD MoneyShow
Feb-27-19 03:09PM  Supernus Pharmaceuticals Inc (SUPN) Q4 2018 Earnings Conference Call Transcript Motley Fool +13.86%
07:00AM  Supernus Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-26-19 04:56PM  Supernus Announces Record Full Year 2018 Financial Results GlobeNewswire
Feb-22-19 09:30AM  Should You Be Worried About Insider Transactions At Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)? Simply Wall St.
Feb-12-19 04:15PM  Supernus to Host Fourth Quarter and Full Year 2018 Earnings Conference Call GlobeNewswire
Feb-02-19 09:21AM  An Intrinsic Calculation For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shows Its 45.76% Undervalued Simply Wall St.
09:12AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
Jan-10-19 09:30AM  MYL vs. SUPN: Which Stock Is the Better Value Option? Zacks
06:23AM  Does Market Volatility Impact Supernus Pharmaceuticals, Inc.s (NASDAQ:SUPN) Share Price? Simply Wall St.
Dec-28-18 11:01AM  Edited Transcript of SUPN earnings conference call or presentation 7-Nov-18 2:00pm GMT Thomson Reuters StreetEvents
Dec-21-18 04:15PM  Supernus to Present at the 2019 J.P. Morgan Healthcare Conference GlobeNewswire -5.63%
Dec-20-18 10:57AM  Supernus Pharma's ADHD drug meets main goal in study on adolescents Reuters
09:56AM  Hedge Funds Arent Crazy About Supernus Pharmaceuticals Inc (SUPN) Anymore Insider Monkey
07:12AM  Supernus Pharma's ADHD drug meets main goal in late-stage trial Reuters
07:00AM  Supernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD GlobeNewswire
Dec-16-18 09:13AM  Why We Think Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Could Be Worth Looking At Simply Wall St.
Dec-14-18 04:02PM  Supernus Announces FDA Approval of sNDA to Expand Oxtellar XR® Label to Include Monotherapy GlobeNewswire
Dec-11-18 06:00AM  3 Top Biotech Stocks to Buy in December Motley Fool
Dec-06-18 12:53PM  This Index Of Leading Stocks Falls Into A Bear Market As Boeing Stings Dow Jones Investor's Business Daily -11.89%
12:33PM  Supernus Pharma's ADHD treatment fails to impress; shares fall Reuters
11:13AM  Here's Why Supernus Pharmaceuticals Is Sinking Today Motley Fool
08:00AM  Consolidated Research: 2018 Summary Expectations for TD Ameritrade Holding, Supernus Pharmaceuticals, Akcea Therapeutics, Dell Technologies, iRobot, and Pegasystems Fundamental Analysis, Key Performance Indications GlobeNewswire
07:56AM  The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering Benzinga
07:11AM  Supernus Pharma's ADHD treatment succeeds in two late-stage studies Reuters
07:00AM  Supernus Announces Positive Results from Two Phase III Studies For SPN-812 in Children with ADHD GlobeNewswire
Dec-05-18 04:12PM  Supernus Schedules Conference Call to Present Topline Results of Two Phase III Studies for SPN-812 in Children with ADHD GlobeNewswire
Dec-04-18 07:00AM  Today's Research Reports on Trending Tickers: Incyte and Supernus Pharmaceuticals ACCESSWIRE -5.83%
Nov-30-18 04:29PM  Stock Market Stages Bullish Reversal To Cap Week With Big Gains Investor's Business Daily +5.97%
Nov-29-18 06:55AM  Today's Research Reports on Trending Tickers: Heron Therapeutics and Supernus Pharmaceuticals ACCESSWIRE
Nov-15-18 11:06AM  What Should Investors Know About Supernus Pharmaceuticals Incs (NASDAQ:SUPN) Future? Simply Wall St.
Nov-07-18 04:39PM  Supernus to Present at Three November Healthcare Conferences GlobeNewswire +8.50%
08:24AM  3 Top Biotech Stocks to Buy in November Motley Fool
Nov-06-18 07:35PM  Supernus Pharmaceuticals (SUPN) Tops Q3 Earnings and Revenue Estimates Zacks
06:32PM  Supernus: 3Q Earnings Snapshot Associated Press
04:15PM  Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue GlobeNewswire
Oct-26-18 08:25AM  Recent Analysis Shows Supernus Pharmaceuticals, GDS HOLDINGS, Golden Ocean Group, Golar LNG, Endo International plc, and 51job Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Oct-24-18 04:30PM  Supernus to Host Third Quarter 2018 Earnings Conference Call GlobeNewswire
Oct-15-18 08:15AM  Supernus Pharmaceuticals (SUPN): Moving Average Crossover Alert Zacks
Oct-10-18 05:17AM  New Strong Sell Stocks for October 10th Zacks
Sep-21-18 03:52PM  Did Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Create Value For Shareholders? Simply Wall St.
Sep-20-18 05:28PM  Supernus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-14-18 01:54PM  Supernus Pharmaceuticals to acquire Miami biotech for up to $185M American City Business Journals
08:38AM  The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut Benzinga
Sep-13-18 04:15PM  Supernus to Acquire Biscayne Neurotherapeutics GlobeNewswire
Sep-07-18 08:18AM  3 Top Biotech Stocks to Buy in September Motley Fool +5.24%
Sep-06-18 03:34PM  Supernus Wins Appeal on Oxtellar XR® against TWi GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Momenta Pharmaceuticals and Supernus Pharmaceuticals ACCESSWIRE
Sep-05-18 05:15PM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
Aug-29-18 04:15PM  Supernus to Present at September 2018 Wells Fargo Healthcare Conference GlobeNewswire
Aug-08-18 04:18PM  IBD 50's Supernus Pharma Topples As Key Epilepsy Drug Sales Lag Investor's Business Daily -8.72%
03:01PM  Why Supernus Pharmaceuticals, Inc. Is Falling Today Motley Fool
03:00PM  Google Owner Defies Stock Market Blues As This Internet Stock Goes En Fuego Investor's Business Daily
07:00AM  Supernus Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-18 07:05PM  Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings Estimates Zacks
05:59PM  Supernus: 2Q Earnings Snapshot Associated Press
04:15PM  Supernus Announces Second Quarter 2018 Financial Results and Record Quarterly Revenue GlobeNewswire
Jul-25-18 04:15PM  Supernus to Host Second Quarter 2018 Earnings Conference Call GlobeNewswire
Jul-20-18 06:00AM  5 Favorite Biotech Bets Investopedia
Jul-19-18 07:50AM  Initiating Free Research Reports on Horizon Pharma and Three Other Healthcare Equities ACCESSWIRE
Jun-27-18 04:30PM  Dr. Carrolee Barlow, M.D., Ph.D., Joins Supernus Board of Directors GlobeNewswire
Jun-24-18 10:38AM  These Factors Make Supernus Pharmaceuticals Inc (NASDAQ:SUPN) A Great Investment Simply Wall St.
Jun-20-18 03:01PM  Brief Commentary On Supernus Pharmaceuticals Incs (NASDAQ:SUPN) Fundamentals Simply Wall St. +5.16%
Jun-18-18 07:05AM  Free Research Reports on Ironwood Pharma and Three More Generic Drugs Stocks ACCESSWIRE
Jun-05-18 07:55AM  Recent Analysis Shows Supernus Pharmaceuticals, R1 RCM, Golar LNG, Chemical Financial, Chipmos Technologies, and Tower Semiconductor Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jun-01-18 09:00AM  Faruqi & Faruqi, LLP is Investigating Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of its Shareholders PR Newswire
May-30-18 10:15AM  Supernus to Present at the 2018 Jefferies Healthcare Conference GlobeNewswire
May-16-18 11:10AM  Breakout Watch: Biotech Stock With 172% Growth Enters Buy Zone Investor's Business Daily
May-15-18 08:51AM  Implied Volatility Surging for Supernus (SUPN) Stock Options Zacks
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIEBERT JOHN MDirectorJun 20Option Exercise9.1310,00091,30055,742Jun 24 08:06 PM
SIEBERT JOHN MDirectorApr 25Option Exercise9.1310,00091,30045,742Apr 29 03:43 PM
PATRICK GREGORY SSr VP, Chief Financial OfficerFeb 27Option Exercise9.1320,000182,60067,896Feb 28 04:29 PM
PATRICK GREGORY SSr VP, Chief Financial OfficerFeb 27Sale41.5320,000830,65047,896Feb 28 04:29 PM
SIEBERT JOHN MDirectorAug 20Option Exercise8.5216,179137,80635,742Mar 04 05:41 PM